Immunorestoration of anergic cancer patients by azimexon.

Abstract	Azimexon, a new synthetic immunoadjuvant, can act on delayed-type hypersensitivity (DTH) reactions. Seven of 11 anergic cancer patients have been immunorestored by a relatively low dosage of azimexon. The effect on the lymphocyte responsiveness, and particularly of a new T-lymphocyte mitogen (TPA), are described. The possible mechanisms of the anergy of the cancer patients and of the mode of action of azimexon are discussed.
Authors	A Goutner, F Nasrat, D Bonardelle, G Rameau
Journal	Recent results in cancer research. Fortschritte der Krebsforschung. Progres dans les recherches sur le cancer (Recent Results Cancer Res) Vol. 75 Pg. 47-52 ( 1980) ISSN: 0080-0015 [Print] Germany
PMID	7232839 (Publication Type: Journal Article)
Chemical References	Adjuvants, Immunologic Aziridines Azirines azimexon Tetradecanoylphorbol Acetate
Topics	Adjuvants, Immunologic (therapeutic use) Aziridines (therapeutic use) Azirines (therapeutic use) Humans Hypersensitivity, Delayed (immunology) Immunotherapy Lymphocytes (drug effects, immunology) Neoplasms (immunology) Tetradecanoylphorbol Acetate (pharmacology)

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!